-
Mashup Score: 1Shorter Duration of Adjuvant Trastuzumab Shows Long-Term Survival Benefit in Select HER2+ Early Breast Cancer - 3 year(s) ago
Although administering trastuzumab for 1 year in patients with HER2-positive early breast cancer continues to be standard, a 9-week de-escalation approach may be a reasonable option in a large proportion of the real-world HER2-positive population.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Retesting for HER2 Upon Breast Cancer Relapse May Provide New Therapeutic Opportunities - 3 year(s) ago
Approximately 30% of breast cancer tumors can covert from, or to, HER2-low status, underscoring the need to retest for HER2 expression upon relapse.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Results indicated that 14% of triple-negative breast cancers with HER2-negative expression in the primary tumor were found to convert to HER2-low expression upon recurrence. @myESMO #ESMOBreast2021 #bcsm https://t.co/5WIRI9yMO4
-
-
Mashup Score: 0High-Grade ILD Prevention With Trastuzumab Deruxtecan Includes Early Detection, Optimal Management in HER2+ Metastatic Breast Cancer - 3 year(s) ago
Effective early detection and optimal management are critical in preventing high-grade interstitial lung disease, a treatment-related adverse effect of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic breast cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Data also showed that the risk of all-grade ILD decreases over time, suggesting that this patient population does not experience cumulative toxicity. @CAP_MDNY @Respiratory_NYC @myESMO #ESMOBreast2021 #bcsm https://t.co/E0eldvGNVh
-
-
Mashup Score: 1HER2+ Breast Cancer With Immune-Related Gene Signatures May Be Eligible for De-Escalation Approaches - 3 year(s) ago
Distinct gene signatures, with the exception of estrogen receptor signaling and BRCAness, are associated with pathologic complete response and invasive disease-free survival, in patients with HER2-positive breast cancer who received trastuzumab and pertuzumab alone or in combination with paclitaxel.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Results indicated that the pCR rate with the addition of paclitaxel to trastuzumab and pertuzumab was 78.6% vs 24.4% with trastuzumab and pertuzumab alone. @myESMO #ESMOBreast2021 #bcsm https://t.co/myxHB2zRLa
-
-
Mashup Score: 1
Thomas Bachelot, MD, discussed how to approach treatment of patients with HER2-positive breast cancer and CNS metastases and the impact of tucatinib in this population.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
For patients with HER2-positive breast cancer who experience central nervous system metastases, the best systemic treatment available will also be the best option for controlling non-progressive brain metastases. @myESMO #ESMOBreast2021 #bcsm https://t.co/c6BRQAK3UP
-
-
Mashup Score: 2Retesting for HER2 Upon Breast Cancer Relapse May Provide New Therapeutic Opportunities - 3 year(s) ago
Approximately 30% of breast cancer tumors can covert from, or to, HER2-low status, underscoring the need to retest for HER2 expression upon relapse.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Approximately 30% of breast cancer tumors can covert from, or to, HER2-low status, underscoring the need to retest for HER2 expression upon relapse. @myESMO #ESMOBreast2021 #bcsm https://t.co/rbW4q51Pq1
-
-
Mashup Score: 0HER2+ Breast Cancer With Immune-Related Gene Signatures May Be Eligible for De-Escalation Approaches - 3 year(s) ago
Distinct gene signatures, with the exception of estrogen receptor signaling and BRCAness, are associated with pathologic complete response and invasive disease-free survival, in patients with HER2-positive breast cancer who received trastuzumab and pertuzumab alone or in combination with paclitaxel.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Distinct gene signatures are associated with pathologic complete response and invasive DFS, in patients with HER2+ breast cancer who received trastuzumab and pertuzumab alone or in combination with paclitaxel. @unihh @myESMO #ESMOBreast2021 #bcsm https://t.co/IzzqBez8of
-
-
Mashup Score: 0Breast Cancer Survivors Need More Tailored Follow-Up Care - 3 year(s) ago
Post-treatment care for breast cancer survivors must be personalized to address each survivor’s unique experiences.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Post-treatment care for breast cancer survivors must be personalized to address each survivor’s unique experiences. @NKI_nl @myESMO #ESMOBreast2021 #bcsm https://t.co/iQC9teCtxs
-
-
Mashup Score: 2Neratinib Shows Numeric OS Benefit, Trend Toward Improved CNS Outcomes in Early-Stage HER2+ Breast Cancer - 3 year(s) ago
Although fewer deaths were reported with neratinib in patients with HER2-positive breast cancer treated on the phase 3 ExteNET trial, the agent was not found to result in a significant improvement in overall survival after 8 years of follow-up.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Neratinib Shows Numeric OS Benefit, Trend Toward Improved CNS Outcomes in Early-Stage HER2+ Breast Cancer @CurtinUni @myESMO #ESMOBreast2021 #bcsm https://t.co/n1zoj1fBMt
-
-
Mashup Score: 1Clinical Benefit With Endocrine Therapy Differs By Risk of Distant Disease Recurrence in Premenopausal ER+ Breast Cancer - 3 year(s) ago
Stratification by the molecular 70-gene risk prediction signature revealed that patients with estrogen receptor–positive breast cancer who are low risk for disease recurrence derive greater benefit from tamoxifen, while those who are high risk have greater benefit from goserelin vs no endocrine therapy.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Clinical Benefit With Endocrine Therapy Differs By Risk of Distant Disease Recurrence in Premenopausal ER+ Breast Cancer @karolinskainst @myESMO #ESMOBreast2021 #bcsm https://t.co/uu8ntpCPaF
-
After a median follow-up of 8.7 years, patients who received 1 year of trastuzumab had a 5-year disease-free survival rate of 87.9% vs 85.8% those who received it for 9 weeks. @myESMO #ESMOBreast2021 #bcsm https://t.co/E2KjcUDz6I